Tris Pharma Inc., a commercial-stage biopharmaceutical company, has promoted Jim Potenziano, Ph.D to the position of Chief Science and Development Officer (CSDO). This corporate update comes as Tris accelerates its growth and advances toward submitting a New Drug Application (NDA) for cebranopadol, an investigational first-in-class dual NOP/MOP receptor (dual-NMR) agonist for the treatment of moderate-to-severe acute pain. “Jim is the ideal leader to bring together the full breadth of Tris...